Navigation Links
Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec®
Date:12/12/2011

cardiac involvement, cardiogenic shock and left ventricular dysfunction have been associated with initiation of GLEEVEC. The condition was reported to be reversible with the administration of systemic steroids, circulatory support measures, and temporarily withholding GLEEVEC.

Bullous dermatologic reactions (eg, erythema multiforme and Stevens-Johnson syndrome) have also been reported. In some cases, the reaction recurred upon rechallenge. Several postmarketing reports describe patients able to tolerate the reintroduction of GLEEVEC at a lower dose with or without concomitant corticosteroids or antihistamines following resolution or improvement of the bullous reaction.

Clinical cases of hypothyroidism have been reported in thyroidectomy patients undergoing levothyroxine replacement during treatment with GLEEVEC. TSH levels should be closely monitored in such patients.

Consider potential toxicities—specifically liver, kidney, and cardiac toxicity—and immunosuppression from long-term use.

Fetal harm can occur when administered to a pregnant woman; therefore, women of childbearing potential should be advised to not become pregnant while taking GLEEVEC tablets and to avoid breast-feeding while taking GLEEVEC tablets because of the potential for serious adverse reactions in nursing infants. Sexually active female patients taking GLEEVEC should use adequate contraception. If the patient does become pregnant while taking GLEEVEC, the patient should be advised of the potential hazard to the fetus.

Growth retardation has been reported in children and pre-adolescents receiving GLEEVEC. The long-term effects of prolonged treatment with GLEEVEC on growth in children are unknown; therefore, monitoring of growth in children taking GLEEVEC is recommended.

Cases of tumor lysis syndrome (TLS), including fatal cases, have been reported. The patients at risk of TLS are those with tumors having a high proliferative rate or high t
'/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... CHAPEL HILL, N.C. , Aug. 28, 2015 ... critical market research projects can slow down the ... costs. It is, therefore, absolutely critical for biopharmaceutical ... the market research approval process for quicker and ... recent research by Best Practices, LLC, nearly three-quarters ...
(Date:8/28/2015)... -- Research and Markets ( ... "Investigation Report on China,s Pranoprofen Market, 2010-2019" ... discovered by Welfide (Mitsubishi Tanabe Pharma Corporation formerly ... inflammatory drug, pranoprofen was later developed into eye ... trade name of pranopulin for the treatment of ...
(Date:8/28/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/jq34zf/investigation ... Report on China,s Tobramycin Market, 2010-2019" report to ... whose eye drop and ointment are the most common ... inflammation caused by eye infection. Currently, dozens of enterprises ... produce tobramycin, among which the Top 5 are s.a. ...
Breaking Medicine Technology:Expediting the Pharmaceutical Market Research Process for Faster Insights 2Investigation Report on China's Pranoprofen Market, 2010-2019 2Investigation Report on China's Tobramycin Market, 2015-2019 2
... Perrigo Company (Nasdaq: PRGO ; ... Cooperation and License agreements with Brilite Nutritionals (Shanghai) ... company. Under these agreements, Perrigo will supply its ... will exclusively source all its infant formula requirements ...
... and HERZLIYA PITUACH, Israel, Nov. 8, 2011 ... -- SMT Research & Development, Ltd. ("SMT") ... as Vice President and General Manager.  Mr. Porath will ... company,s development and production facility in Herzliya Pituach, Israel, ...
Cached Medicine Technology:Perrigo Expands Infant Formula Distribution in China With Brilite Nutritionals (Shanghai) Co., Ltd. 2SMT Research & Development, Ltd. Names Shuki Porath as Vice President and General Manager, Announces TCT Presence 2SMT Research & Development, Ltd. Names Shuki Porath as Vice President and General Manager, Announces TCT Presence 3
(Date:8/30/2015)... , ... August 31, 2015 , ... ... and a third of tax receipts, issues that are critically important to them ... bands of attorneys and lobbyists monitoring proposed legislation and changing tax and regulatory ...
(Date:8/30/2015)... (PRWEB) , ... August 31, 2015 , ... ... Magazine: The Fun Cooking Magazine for Kids , recently elected two new officers ... These appointments will further ChopChop’s mission of inspiring and teaching kids to cook ...
(Date:8/30/2015)... ... August 30, 2015 , ... ... today announced it is a Silver Sponsor of the Digital Workplace Conference, taking ... Centre in Auckland, NZ. Throughout the event, AvePoint will showcase its file analysis, ...
(Date:8/30/2015)... Boca Raton, Fl (PRWEB) , ... August 30, ... ... that Brian Spector has joined the company as the new Global Communications Director ... broadcasting and public relations experience having spent the last 16 years doing on-air ...
(Date:8/30/2015)... Raton, Fl (PRWEB) , ... August 30, 2015 ... ... that Executive Vice President Jeff Fernandez will lead the expansion of global cosmeceutical ... cosmeceutical and skin care experience having spent the last 25 years working in ...
Breaking Medicine News(10 mins):Health News:Newport Board Group, an Advisory Firm Serving the Middle Market, Issues Five Tips on Selling Services to the Government 2Health News:Newport Board Group, an Advisory Firm Serving the Middle Market, Issues Five Tips on Selling Services to the Government 3Health News:Newport Board Group, an Advisory Firm Serving the Middle Market, Issues Five Tips on Selling Services to the Government 4Health News:ChopChop Kids Appoints New Chair and Vice-Chair to Board of Directors 2Health News:ChopChop Kids Appoints New Chair and Vice-Chair to Board of Directors 3Health News:AvePoint Showcases the Future of Enterprise Collaboration as Silver Sponsor of the Digital Workplace Conference in New Zealand 2Health News:AvePoint Showcases the Future of Enterprise Collaboration as Silver Sponsor of the Digital Workplace Conference in New Zealand 3Health News:AvePoint Showcases the Future of Enterprise Collaboration as Silver Sponsor of the Digital Workplace Conference in New Zealand 4Health News:InHealth Media Appoints New Global Communications Director 2Health News:NPI Executive Vice President Leads Cosmeceutical Expansion 2
... As ... be welcoming world leaders to the David L. Lawrence Convention Center, the largest "green" ... Design) certification. , ... Pittsburgh, Pa. (PRWEB) September 24, 2009 -- As the industry leader in automatic door ...
... , , , SEATTLE, ... launched the Living Proof Project: U.S. Investments in Global Health ... success of the U.S. government,s efforts to improve health around ... Project will show that U.S.-supported initiatives to fight malaria, AIDS, ...
... , , , INDIANAPOLIS, ... District of Indiana today upheld Eli Lilly and Company,s (NYSE: ... tablets). In the case of Eli Lilly and Company ... favor of Lilly on all accounts for these method-of-use patents, ...
... , , , ... Northern Ireland, moderated by President Clinton, featured Peter Robinson, first ... Northern Ireland Executive; Declan Kelly, economic envoy to Northern Ireland, ... Northern Ireland; and Micheal Martin, Minster of Foreign ...
... Sept. 23 Allowing age adjustments more restrictive than 5 to ... in the individual insurance market, making coverage unaffordable for many according ... Cross and Blue Shield Association (BCBSA) released today new data, prepared ... that a 2 to 1 age rating ratio would increase premiums ...
... NEW YORK, Sept. 23 The Michael J. ... to successfully translate neurotrophic factor advances from pre-clinical and early-phase ... The funding will be awarded under a new Directed ... , , The Foundation,s intention is to ...
Cached Medicine News:Health News:BEA Opens the Doors to the World at G20 Summit 2Health News:BEA Opens the Doors to the World at G20 Summit 3Health News:Gates Foundation Launches Campaign to Highlight Success of U.S. Global Health Investments 2Health News:Gates Foundation Launches Campaign to Highlight Success of U.S. Global Health Investments 3Health News:U.S. District Court Upholds Validity of Lilly's Evista Patents Through 2014 2Health News:U.S. District Court Upholds Validity of Lilly's Evista Patents Through 2014 3Health News:President Clinton Hosts Special Session on Northern Ireland; Announces New Commitments Focused on Harnessing Innovation for Development 2Health News:President Clinton Hosts Special Session on Northern Ireland; Announces New Commitments Focused on Harnessing Innovation for Development 3Health News:President Clinton Hosts Special Session on Northern Ireland; Announces New Commitments Focused on Harnessing Innovation for Development 4Health News:President Clinton Hosts Special Session on Northern Ireland; Announces New Commitments Focused on Harnessing Innovation for Development 5Health News:President Clinton Hosts Special Session on Northern Ireland; Announces New Commitments Focused on Harnessing Innovation for Development 6Health News:President Clinton Hosts Special Session on Northern Ireland; Announces New Commitments Focused on Harnessing Innovation for Development 7Health News:President Clinton Hosts Special Session on Northern Ireland; Announces New Commitments Focused on Harnessing Innovation for Development 8Health News:President Clinton Hosts Special Session on Northern Ireland; Announces New Commitments Focused on Harnessing Innovation for Development 9Health News:Analysis Shows Narrow Age Rating Would Raise Premiums by Nearly 50 Percent, Causing Many Young and Healthy to Forgo Coverage 2Health News:Michael J. Fox Foundation Commits Up to $5 Million to Help Advance Neurotrophic Factors 'From Promise to Reality' As Parkinson's Treatment 2
... this is the universal lithotripter for ... urinary and biliary treatment. The system ... with other applications including cystoscopy, ureteronoscopy, ... system comprises the height adjustable urologist' ...
... This therapeutic system ... the patient in mind. ... surgery and ongoing therapy, ... low-risk and effective therapy. ...
... Reach a new dimension! That of the ... unequalled performance and ease of use. Enjoy ... electroconductive shock wave technology coupled with the ... system. Manage the patient treatment, X-ray and ...
... The MINILITH SL1 developed by STORZ ... of extensive experience in the field of ... of the specific requirements to be met ... therapy, as has been outlined above. The ...
Medicine Products: